ValuEngine Upgrades Surgery Partners (SGRY) to “Hold”

ValuEngine upgraded shares of Surgery Partners (NASDAQ:SGRY) from a sell rating to a hold rating in a report published on Thursday morning.

Several other equities research analysts also recently commented on SGRY. Zacks Investment Research raised shares of Surgery Partners from a sell rating to a hold rating in a research report on Thursday, April 12th. BidaskClub downgraded shares of Surgery Partners from a strong-buy rating to a buy rating in a research report on Thursday, April 12th. Stifel Nicolaus decreased their target price on shares of Surgery Partners from $17.00 to $15.00 and set a sell rating for the company in a research report on Tuesday, April 10th. Jefferies Group set a $18.00 target price on shares of Surgery Partners and gave the stock a buy rating in a research report on Thursday, March 1st. Finally, Benchmark set a $19.00 target price on shares of Surgery Partners and gave the stock a buy rating in a research report on Tuesday, January 30th. One research analyst has rated the stock with a sell rating, five have given a hold rating and five have given a buy rating to the company. The stock has an average rating of Hold and a consensus target price of $18.29.

How to Become a New Pot Stock Millionaire

SGRY traded up $0.07 during midday trading on Thursday, hitting $18.17. The company had a trading volume of 89,928 shares, compared to its average volume of 358,249. Surgery Partners has a 52 week low of $7.10 and a 52 week high of $24.05. The company has a current ratio of 1.86, a quick ratio of 1.71 and a debt-to-equity ratio of 1.59. The company has a market cap of $849.49, a P/E ratio of -21.55 and a beta of 1.82.

Surgery Partners (NASDAQ:SGRY) last posted its quarterly earnings results on Thursday, March 1st. The company reported ($0.03) earnings per share for the quarter, missing the consensus estimate of $0.08 by ($0.11). The company had revenue of $460.30 million during the quarter, compared to the consensus estimate of $438.30 million. Surgery Partners had a negative net margin of 4.54% and a negative return on equity of 0.53%. The company’s revenue for the quarter was up 50.4% on a year-over-year basis. During the same period last year, the firm posted $0.35 earnings per share. research analysts forecast that Surgery Partners will post -0.14 EPS for the current fiscal year.

Several large investors have recently bought and sold shares of the company. BlackRock Inc. grew its position in Surgery Partners by 0.5% in the 4th quarter. BlackRock Inc. now owns 1,306,021 shares of the company’s stock worth $15,804,000 after purchasing an additional 7,029 shares in the last quarter. We Are One Seven LLC bought a new stake in Surgery Partners in the 4th quarter worth about $138,000. BlueCrest Capital Management Ltd bought a new stake in Surgery Partners in the 4th quarter worth about $157,000. Kennedy Capital Management Inc. grew its position in Surgery Partners by 2.8% in the 4th quarter. Kennedy Capital Management Inc. now owns 498,556 shares of the company’s stock worth $6,033,000 after purchasing an additional 13,659 shares in the last quarter. Finally, Aperio Group LLC bought a new stake in Surgery Partners in the 4th quarter worth about $173,000.

ILLEGAL ACTIVITY NOTICE: “ValuEngine Upgrades Surgery Partners (SGRY) to “Hold”” was posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this news story on another site, it was stolen and reposted in violation of US and international copyright and trademark laws. The original version of this news story can be viewed at https://www.dispatchtribunal.com/2018/04/20/valuengine-upgrades-surgery-partners-sgry-to-hold.html.

About Surgery Partners

Surgery Partners, Inc is healthcare services holding company, which engages in the provision of solutions for surgical and related ancillary care in support of its patients and physicians. It operates through the following business segments: Surgical Facility Services; Ancillary Services; and Optical Services.

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for Surgery Partners (NASDAQ:SGRY)

Receive News & Ratings for Surgery Partners Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Surgery Partners and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply